Physician profile
Anna C Maio
NPI 1871684126
$280.56
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $118.24 | 2019 | |
| Insulet Corporation | $40.81 | 2019 | |
| Abbott Laboratories | $35.82 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $17.47 | 2019 | |
| Lilly USA, LLC | $15.65 | 2019 | |
| Antares Pharma, INC. | $13.98 | 2019 | |
| Novo Nordisk INC | $13.43 | 2019 | |
| Viiv Healthcare Company | $12.93 | 2019 | |
| Tandem Diabetes Care, INC. | $12.23 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Maio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.